source
- GSK discontinues its chronic cough therapy amid uncertain futureGSK has announced that it is ending development of its chronic cough treatment. The decision marks the conclusion of the program that had been under investigation for several years. The article do…
- Dimerix acquires Mission’s acute kidney injury candidate for $5 million upfrontDimerix announced it has signed a deal to acquire a kidney injury drug candidate from Mission Therapeutics. The asset is ready to enter Phase 2 trials for the treatment of acute kidney injury. Und…